文献速递头颈与中枢神经肿瘤

弥漫浸润性少突胶质细胞瘤与星形细胞瘤

Diffuse Infiltrating Oligodendroglioma and Astrocytoma.
PubMed 文献 · J Clin Oncol · 2017-06-22

2016年WHO脑肿瘤分类主要依据IDH突变和1p/19q联合缺失定义弥漫性胶质瘤。IDH突变型预后较好,IDH野生型异质性大且部分具胶质母细胞瘤样分子特征。放化疗联合较单纯放疗改善生存,但单纯化疗与单纯放疗无生存差异,化疗获益预测因素尚未确立。

要点

  • 间变性少突胶质细胞瘤诊断需同时具备IDH突变和1p/19q共缺失。
  • IDH野生型肿瘤异质性大,部分具胶质母细胞瘤样分子特征且预后差。
  • II或III级胶质瘤术后首选放疗联合化疗,单纯化疗与单纯放疗无生存差异。

核心结论

  • IDH突变型弥漫性胶质瘤预后较好,低级别组织学肿瘤尤其倾向于缓慢进展。
  • IDH野生型肿瘤并非均一实体,部分具胶质母细胞瘤样分子特征且临床结局差,需进一步分子检测。
  • 对新诊断II或III级胶质瘤,放疗联合化疗较单纯放疗初始治疗有生存获益,而单纯化疗与单纯放疗相比未观察到生存差异。
  • 目前对术后需治疗的II或III级胶质瘤,首选治疗为放疗联合化疗。
  • II和III级胶质瘤化疗获益的最佳预测因素仍有待确立。

研究设计与样本

  • 本文为综述,围绕2016年WHO脑肿瘤分类下弥漫浸润性少突胶质细胞瘤与星形细胞瘤的诊断、分子特征与治疗进行总结。

主要发现

  • 间变性少突胶质细胞瘤诊断需IDH突变和1p/19q共缺失同时存在,间变性星形细胞瘤分为IDH野生型和IDH突变型。
  • IDH突变型肿瘤预后较好,低级别组织学肿瘤尤其倾向于缓慢进展。
  • IDH野生型肿瘤异质性大,部分具胶质母细胞瘤样分子特征且临床结局差。
  • 新诊断II或III级胶质瘤试验显示,放疗联合化疗较单纯放疗初始治疗有生存获益。
  • 替莫唑胺及丙卡巴肼、洛莫司汀和长春新碱联合方案均提供生存获益。

关键数值与推荐

  • 间变性少突胶质细胞瘤诊断标准为IDH突变和1p/19q共缺失同时存在。
  • 间变性星形细胞瘤分为IDH野生型和IDH突变型。
  • 新诊断II或III级胶质瘤中,放疗联合化疗较单纯放疗有生存获益。
  • 替莫唑胺及丙卡巴肼、洛莫司汀和长春新碱联合方案均提供生存获益。
  • 单纯化疗与单纯放疗相比未观察到生存差异。

临床怎么用

  • 对术后需治疗的II或III级胶质瘤患者,首选治疗为放疗联合化疗。
  • 手术切除应尽可能广泛且安全可行。
  • 治疗还包括放疗和化疗。
  • 决定术后放化疗时机时,应同时考虑临床和分子因素。
  • 部分具有良好特征的低级别胶质瘤患者,初期可考虑更保守的方法。

局限性

  • II和III级胶质瘤化疗获益的最佳预测因素仍有待确立。
  • IDH野生型肿瘤异质性大,需进一步分子检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The new 2016 WHO brain tumor classification defines different diffuse gliomas primarily according to the presence or absence of IDH mutations ( IDH-mt) and combined 1p/19q loss. Today, the diagnosis of anaplastic oligodendroglioma requires the presence of both IDH-mt and 1p/19q co-deletion, whereas anaplastic astrocytoma is divided into IDH wild-type ( IDH-wt) and IDH-mt tumors. IDH-mt tumors have a more favorable prognosis, and tumors with low-grade histology especially tend evolve slowly. IDH-wt tumors are not a homogeneous entity and warrant further molecular testing because some have glioblastoma-like molecular features with poor clinical outcome. Treatment consists of a resection that should be as extensive as safely possible, radiotherapy, and chemotherapy. Trials of patients with newly diagnosed grade II or III glioma have shown survival benefit from adding chemotherapy to radiotherapy compared with initial treatment using radiotherapy alone. Both temozolomide and the combination of procarbazine, lomustine, and vincristine provide survival benefit. In contrast, trials that compare single modality treatment of chemotherapy alone with radiotherapy alone did not observe survival differences. Currently, for patients with grade II or III gliomas who require postsurgical treatment, the preferred treatment consists of a combination of radiotherapy and chemotherapy. Low-grade gliomas with favorable characteristics are slow-growing tumors. When deciding on the timing of postsurgical treatment with radiotherapy and chemotherapy, both clinical and molecular factors should be taken into account, but a more conservative approach can be considered initially in some of these patients. The factor that best predicts benefit of chemotherapy in grade II and III glioma remains to be established.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. van den Bent MJ, Smits M, Kros JM, et al. Diffuse Infiltrating Oligodendroglioma and Astrocytoma. J Clin Oncol. 2017. PMID: 28640702. doi:10.1200/JCO.2017.72.6737

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。